LUNG Pulmonx Corporation Stock Quote

LUNG [NASD]

Index	-	P/E	-	EPS (ttm)	-1.24	Insider Own	4.00%	Shs Outstand	36.45M	Perf Week	-17.49%
Market Cap	907.30M	Forward P/E	-	EPS next Y	-1.24	Insider Trans	-12.45%	Shs Float	33.81M	Perf Month	-25.86%
Income	-45.00M	PEG	-	EPS next Q	-0.36	Inst Own	98.60%	Short Float	4.72%	Perf Quarter	-39.92%
Sales	44.50M	P/S	20.39	EPS this Y	-48.00%	Inst Trans	5.50%	Short Ratio	4.17	Perf Half Y	-40.75%
Book/sh	5.56	P/B	4.28	EPS next Y	8.90%	ROA	-18.80%	Target Price	49.33	Perf Year	-63.83%
Cash/sh	5.25	P/C	4.54	EPS next 5Y	37.70%	ROE	-22.30%	52W Range	24.45 - 68.76	Perf YTD	-25.72%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-13.40%	52W High	-65.36%	Beta	-
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	72.90%	52W Low	-2.58%	ATR	1.94
Employees	170	Current Ratio	10.20	Sales Q/Q	25.50%	Oper. Margin	-	RSI (14)	26.25	Volatility	7.27% 6.41%
Optionable	Yes	Debt/Eq	0.09	EPS Q/Q	-158.10%	Profit Margin	-	Rel Volume	1.21	Prev Close	24.63
Shortable	Yes	LT Debt/Eq	0.07	Earnings	Nov 02 AMC	Payout	-	Avg Volume	382.89K	Price	23.82
Recom	1.80	SMA20	-22.72%	SMA50	-27.94%	SMA200	-38.92%	Volume	462,707	Change	-3.29%

Dec-08-21

Upgrade

Piper Sandler

Neutral → Overweight

$45

Apr-01-21

Initiated

Citigroup

Buy

$60

Mar-25-21

Initiated

Piper Sandler

Neutral

$50

Mar-10-21

Upgrade

BofA Securities

Neutral → Buy

$72

Jan-04-21

Downgrade

BofA Securities

Buy → Neutral

Oct-26-20

Initiated

Wells Fargo

Equal Weight

$46

Oct-26-20

Initiated

Stifel

Buy

$50

Oct-26-20

Initiated

Morgan Stanley

Equal-Weight

$44

Oct-26-20

Initiated

Canaccord Genuity

Buy

$49

Oct-26-20

Initiated

BofA Securities

Buy

$50

Jan-17-22 06:36AM	Investors one-year losses grow to 53% as the stock sheds US$91m this past week Simply Wall St.
Jan-12-22 02:58PM	Hedge Funds Are Buying Pulmonx Corporation (LUNG) Insider Monkey
Jan-04-22 10:00AM	Wall Street Analysts See a 53% Upside in Pulmonx Corporation (LUNG): Can the Stock Really Move This High? Zacks
Dec-29-21 04:05PM	Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-24-21 12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-18-21 09:15AM	Pulmonx Corp (LUNG) President and CEO Glendon E. French Iii Sold $776,250 of Shares GuruFocus.com
12:38AM	Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ... GuruFocus.com
Dec-08-21 07:21AM	10 Pharmaceutical Stocks to Buy According to Efrem Kamens Pura Vida Investments Insider Monkey +6.32%
Nov-17-21 11:58AM	Pulmonx Insider Sold Over $280K In Company Stock Benzinga
Nov-16-21 04:05PM	Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference GlobeNewswire
Nov-03-21 08:00AM	Pulmonx to Participate at Upcoming Investor Conferences GlobeNewswire +7.93%
04:01AM	Pulmonx Corporation (LUNG) Q3 2021 Earnings Call Transcript Motley Fool
Nov-02-21 06:45PM	Pulmonx Corporation (LUNG) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:05PM	Pulmonx Reports Third Quarter 2021 Financial Results GlobeNewswire
07:52AM	The Daily Biotech Pulse: Pfizer Reports Solid Q3 Earnings, Regulatory Setback For Legend, Lilly to Supply Additional COVID-19 Antibody Cocktails To US Benzinga
Oct-27-21 12:35PM	Is Pulmonx Corporation (LUNG) A Good Stock To Buy? Insider Monkey
Oct-26-21 04:05PM	Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021 GlobeNewswire
Oct-20-21 09:08AM	Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level Wall Street Analysts Expect? Zacks
Sep-21-21 04:05PM	Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment Business Wire
10:44AM	President And CEO Of Pulmonx Sold $1.85 Million In Stock Benzinga
Sep-07-21 05:00PM	3 Healthcare Stocks That Might Skyrocket When COVID Is Over Motley Fool
Aug-26-21 04:05PM	Pulmonx to Present at Upcoming September Investor Conferences GlobeNewswire
Aug-20-21 04:30PM	Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment Business Wire
Aug-04-21 09:01AM	Pulmonx Corporation (LUNG) Q2 2021 Earnings Call Transcript Motley Fool
Aug-03-21 04:05PM	Pulmonx Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-02-21 08:45AM	Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks GlobeNewswire
Jul-29-21 04:05PM	Pulmonx to Present at the Canaccord Genuity 41st Annual Growth Conference GlobeNewswire
Jul-27-21 09:14AM	Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema Business Wire
Jul-20-21 06:45PM	3 Small-Cap Healthcare Stocks Worth a Look Motley Fool
04:05PM	Pulmonx to Report Second Quarter 2021 Financial Results on August 3, 2021 GlobeNewswire
Jul-19-21 04:28AM	Have Insiders Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares? Simply Wall St.
Jul-13-21 01:41PM	Is Pulmonx Corporation (LUNG) A Good Stock To Buy Now? Insider Monkey
May-17-21 04:05PM	Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema GlobeNewswire
May-07-21 01:51AM	Pulmonx Corporation (NASDAQ:LUNG) Released Earnings Last Week And Analysts Lifted Their Price Target To US$60.14 Simply Wall St.
May-05-21 04:31AM	Pulmonx Corporation (LUNG) Q1 2021 Earnings Call Transcript Motley Fool -8.26%
May-04-21 04:02PM	Pulmonx Reports First Quarter 2021 Financial Results GlobeNewswire
04:01PM	Pulmonx Corporation Expands Leadership Team GlobeNewswire
02:30PM	Pulmonx Corp to Host Earnings Call ACCESSWIRE
Apr-27-21 04:05PM	Pulmonx to Present at BofA Securities 2021 Virtual Health Care Conference GlobeNewswire
Apr-20-21 04:05PM	Pulmonx to Report First Quarter 2021 Financial Results on May 4, 2021 GlobeNewswire
Mar-10-21 10:03AM	Benzinga's Top Ratings Upgrades, Downgrades For March 10, 2021 Benzinga +11.48%
Mar-04-21 01:30AM	Here's What Pulmonx Corporation's (NASDAQ:LUNG) Shareholder Ownership Structure Looks Like Simply Wall St.
Mar-02-21 10:00PM	Pulmonx Corporation (LUNG) Q4 2020 Earnings Call Transcript Motley Fool
04:01PM	Pulmonx Reports Fourth Quarter and Full Year 2020 Financial Results GlobeNewswire
02:30PM	Pulmonx Corp to Host Earnings Call ACCESSWIRE
Feb-16-21 04:01PM	Pulmonx to Report Fourth Quarter and Full Year 2020 Financial Results on March 2, 2021 GlobeNewswire
Jan-28-21 09:02AM	JTV®, Pulmonx® Corporation & Respiratory Health Association® Launch 2021 Catch Your Breath® Campaign PR Newswire +7.37%
Jan-01-21 12:54AM	Who Has Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares? Simply Wall St.
Dec-08-20 08:13AM	Pulmonx Welcomes Two New Members to Its Board of Directors, Adding Expertise in Consumer Marketing and Medical Device Company Growth GlobeNewswire
Nov-30-20 08:00AM	Over 20,000 Patients Treated with the Non-Surgical Zephyr Valve for Severe Emphysema, a Form of COPD GlobeNewswire
Nov-10-20 04:01PM	Pulmonx Reports Third Quarter 2020 Financial Results GlobeNewswire
02:45PM	Pulmonx Corp to Host Earnings Call ACCESSWIRE
Nov-03-20 08:00AM	Pulmonx to Present at Upcoming Investor Conferences GlobeNewswire +9.50%
Nov-02-20 10:00AM	Pulmonx Announces Additional 16 Million Covered Lives for The Zephyr® Valve, a Minimally Invasive Treatment Option for Severe Emphysema (COPD) GlobeNewswire
Oct-22-20 04:01PM	Pulmonx to Report Third Quarter 2020 Financial Results on November 10, 2020 GlobeNewswire
Oct-05-20 04:01PM	Pulmonx Announces Closing of Initial Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire +10.31%
Oct-02-20 11:23AM	3 Biotech Companies Are Making Their Market Debuts Barrons.com +6.59%
Oct-01-20 12:09PM	Pulmonx shares surge on first day of trading Yahoo Finance Video
11:57AM	Biotech Pulmonx Shares Climb in Trading Debut Barrons.com
11:36AM	Pulmonx shares soar 118% in trading debut MarketWatch
Sep-30-20 10:36PM	Pulmonx Corporation Announces Pricing of its Upsized Initial Public Offering GlobeNewswire

Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
French Glendon E. III	President and CEO	Dec 16	Sale	31.05	25,000	776,220	1,113,949	Dec 17 08:06 PM
Rose Geoffrey Beran	Chief Commercial Officer	Dec 15	Sale	30.55	22,000	672,002	123,459	Dec 16 06:22 PM
Sung Derrick	Chief Financial Officer	Dec 15	Sale	30.53	3,000	91,585	225,420	Dec 16 05:48 PM
Sung Derrick	Chief Financial Officer	Dec 14	Sale	32.89	3,000	98,670	228,420	Dec 16 05:48 PM
French Glendon E. III	President and CEO	Dec 01	Sale	32.73	1,421	46,509	1,138,949	Dec 03 07:11 PM
Lehman David Aaron	General Counsel	Dec 01	Sale	32.73	383	12,536	16,834	Dec 03 06:41 PM
Rose Geoffrey Beran	Chief Commercial Officer	Dec 01	Sale	32.73	355	11,619	145,459	Dec 03 06:39 PM
Sung Derrick	Chief Financial Officer	Dec 01	Sale	32.73	383	12,536	231,420	Dec 03 06:34 PM
French Glendon E. III	President and CEO	Nov 18	Sale	35.98	25,000	899,471	1,105,370	Nov 22 06:44 PM
Rose Geoffrey Beran	Chief Commercial Officer	Nov 15	Sale	39.94	7,000	279,580	145,814	Nov 16 06:09 PM
French Glendon E. III	President and CEO	Oct 21	Sale	39.75	25,000	993,681	1,130,370	Oct 22 07:11 PM
Rose Geoffrey Beran	Chief Commercial Officer	Oct 15	Sale	39.44	7,000	276,080	152,814	Oct 18 08:09 PM
Sung Derrick	Chief Financial Officer	Sep 21	Sale	37.50	3,000	112,500	231,803	Sep 21 08:11 PM
Sung Derrick	Chief Financial Officer	Sep 20	Sale	37.35	3,000	112,062	234,803	Sep 21 08:11 PM
French Glendon E. III	President and CEO	Sep 20	Sale	37.36	23,571	880,624	0	Sep 20 08:45 PM
French Glendon E. III	President and CEO	Sep 16	Sale	38.86	25,000	971,500	1,155,370	Sep 20 08:45 PM
Rose Geoffrey Beran	Chief Commercial Officer	Sep 15	Sale	38.12	7,000	266,840	159,814	Sep 17 06:42 PM
Sung Derrick	Chief Financial Officer	Sep 01	Sale	40.09	383	15,354	237,803	Sep 03 05:58 PM
Rose Geoffrey Beran	Chief Commercial Officer	Sep 01	Sale	40.09	355	14,232	166,814	Sep 03 05:55 PM
Lehman David Aaron	General Counsel	Sep 01	Sale	40.09	383	15,354	17,217	Sep 03 05:53 PM
French Glendon E. III	President and CEO	Sep 01	Sale	40.09	1,421	56,968	1,180,370	Sep 03 05:50 PM
French Glendon E. III	President and CEO	Aug 19	Sale	36.59	1,000	36,590	23,571	Aug 23 06:31 PM
French Glendon E. III	President and CEO	Aug 19	Sale	36.63	25,000	915,750	1,181,791	Aug 23 06:31 PM
Rose Geoffrey Beran	Chief Commercial Officer	Aug 16	Sale	36.71	7,000	256,970	166,885	Aug 18 08:09 PM
French Glendon E. III	President and CEO	Jul 15	Option Exercise	2.20	4,375	9,625	1,231,734	Jul 19 07:48 PM
Rose Geoffrey Beran	Chief Commercial Officer	Jul 15	Sale	38.73	7,000	271,080	173,885	Jul 19 07:49 PM
French Glendon E. III	President and CEO	Jul 15	Sale	38.70	1,000	38,703	24,571	Jul 19 07:48 PM
French Glendon E. III	President and CEO	Jul 15	Sale	38.73	25,000	968,204	1,206,734	Jul 19 07:48 PM
BOSTON SCIENTIFIC CORP	10% Owner	Jul 13	Sale	37.45	2,500,000	93,625,000	1,488,106	Jul 14 04:10 PM
Florin Daniel P	Director	Jul 12	Buy	40.00	2,500	100,000	7,532	Jul 13 07:21 PM
Florin Daniel P	Director	Jun 25	Buy	44.12	2,222	98,035	5,032	Jun 28 05:33 PM
French Glendon E. III	President and CEO	Jun 17	Option Exercise	2.20	4,375	9,625	1,252,359	Jun 21 06:26 PM
French Glendon E. III	President and CEO	Jun 17	Sale	42.68	1,000	42,680	25,571	Jun 21 06:26 PM
French Glendon E. III	President and CEO	Jun 17	Sale	42.96	25,000	1,073,905	1,227,359	Jun 21 06:26 PM
Rose Geoffrey Beran	Chief Commercial Officer	May 24	Sale	40.88	4,797	196,085	163,285	May 25 05:18 PM
French Glendon E. III	President and CEO	May 20	Sale	40.75	1,000	40,750	26,571	May 21 05:25 PM
French Glendon E. III	President and CEO	May 20	Sale	41.95	25,000	1,048,780	1,199,884	May 21 05:25 PM
Rose Geoffrey Beran	Chief Commercial Officer	May 18	Option Exercise	1.40	49,428	69,199	166,101	May 19 05:19 PM
Rose Geoffrey Beran	Chief Commercial Officer	May 10	Sale	40.70	4,797	195,247	116,673	May 11 06:58 PM
Rose Geoffrey Beran	Chief Commercial Officer	Apr 19	Sale	43.24	4,797	207,422	121,470	Apr 21 05:26 PM
French Glendon E. III	President and CEO	Apr 15	Sale	43.70	1,000	43,700	27,571	Apr 16 05:03 PM
French Glendon E. III	President and CEO	Apr 15	Sale	43.75	25,000	1,093,856	1,224,884	Apr 16 05:03 PM
BOSTON SCIENTIFIC CORP	10% Owner	Apr 06	Sale	43.60	650,000	28,340,000	3,988,106	Apr 08 04:20 PM
Sung Derrick	Chief Financial Officer	Apr 06	Sale	47.12	5,000	235,602	218,659	Apr 06 07:40 PM
Rose Geoffrey Beran	Chief Commercial Officer	Apr 05	Sale	47.64	4,797	228,521	109,064	Apr 06 07:41 PM
Sung Derrick	Chief Financial Officer	Apr 05	Sale	47.60	5,000	238,020	223,659	Apr 06 07:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience